title: Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.
authors.forename: J
authors.initials: J
authors.lastname: Rosenstock
authors.forename: V
authors.initials: V
authors.lastname: Fonseca
authors.forename: J B
authors.initials: JB
authors.lastname: McGill
authors.forename: M
authors.initials: M
authors.lastname: Riddle
authors.forename: J P
authors.initials: JP
authors.lastname: Hallé
authors.forename: I
authors.initials: I
authors.lastname: Hramiak
authors.forename: P
authors.initials: P
authors.lastname: Johnston
authors.forename: M
authors.initials: M
authors.lastname: Davis
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D003930:Diabetic Retinopathy / Q000453:epidemiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives*; D000069036:Insulin Glargine; D007336:Insulin, Isophane / Q000009:adverse effects*; D049528:Insulin, Long-Acting; D009369:Neoplasms / Q000453:epidemiology*; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine; D007336:Insulin, Isophane